Live feed06:45:00·4mPRReleasevia QuantisnowMerck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular EdemaByQuantisnow·Wall Street's wire, on your screen.MRK· Merck & Company Inc.Health Care
